Dentsply Sirona today announced that it has acquired Datum Dental, Ltd. with its strong OSSIX® biomaterial portfolio. Datum Dental is an Israel-based company, known for its innovative dental regeneration products with the clinically superior proprietary technology GLYMATRIX®. Datum Dental complements Dentsply Sirona’s existing implant dentistry strategy around Ankylos, Astra Tech Implant System, Xive and Atlantis, focusing on established quality and meaningful innovation. In addition, Datum Dental has a strong R&D pipeline with many promising products with differentiated value propositions and Dentsply Sirona has the capacity to further invest in its future development.
The acquisition of Datum Dental will open up significant opportunities for Dentsply Sirona within its Implants segment. With a track record of simplifying and developing innovations for regenerative procedures, the OSSIX® portfolio will support the vision to become one of the leaders in the dental regeneration industry. With innovative products driven by the GLYMATRIX® core technology, OSSIX® bio-durable design will ensure long-term predictable and superior results. The OSSIX® dental regeneration products will support and enhance the future of implant dentistry and oral care.
“Datum Dental perfectly fits in our strategy to deliver innovative and meaningful solutions for our customers. The biomaterial sector is an important cornerstone of the future of dentistry. The acquisition is another important step for us to deliver on our purpose to empower dental professionals to provide patients with better dental care and make people smile,” says Gene Dorff, Group Vice President Implants Product Group of Dentsply Sirona.
“We are pleased that the OSSIX® family is becoming part of the market leader in dental. Dentsply Sirona offers us opportunities to work on continued innovation with the strongest R&D team in the industry. Our R&D pipeline will continue to develop new, safe and transformational solutions – that simplify procedures and overcome major deficiencies in existing biomaterial‐based regenerative products,” says Itay Itzhaky, Chief Executive Officer of Datum Dental.
Since 2016, Dentsply Sirona has already been in distribution agreements with Datum Dental. Today, Dentsply Sirona is promoting the full OSSIX® portfolio (OSSIX® Plus, OSSIX® Volumax, and OSSIX™ Bone) in the U.S., Canada, Colombia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey and Hong Kong.
Clinicians will benefit in the future from OSSIX® products’ being implemented in a broad set of solutions and workflows and Dentsply Sirona’s capacity to invest in the future development. The strong OSSIX® portfolio will be the foundation of the Regenerative portfolio of Dentsply Sirona. The transaction is expected to close in January 2021, following customary approval requirements.
About Datum Dental
Datum Dental is an innovative Israel-based company for dental regeneration products with clinically superior proprietary technology. The company markets its products for dental professionals through its extensive global network of partners in over 40 countries worldwide. The company was founded in 2012, has 50 employees and its headquarters is in Lod, close to Tel Aviv, Israel.
Datum Dental is a leading provider of the innovative OSSIX® regenerative solutions portfolio. Powered by the company’s patented GLYMATRIX® technology, OSSIX® Plus, OSSIX® Volumax, and OSSIX™ Bone are covered by over 100 scientific publications and extensive clinical experience with thousands of clinicians. The company uses its proprietary GLYMATRIX® core technology, a proven process that uses naturally occurring sugar to cross-link collagen biomaterial, for guided bone regeneration (GBR) and guided tissue regeneration (GTR). The OSSIX® product portfolio has enabled clinicians in hundreds of thousands of procedures in over 40 countries to safely provide predictable, long-term results to their patients over the past 20 years.